Sanofi, the French pharmaceutical giant, has announced plans to invest at least $20 billion in the United States by 2030. The commitment includes a major boost to research and development spending, as well as billions allocated toward expanding U.S.-based manufacturing operations.
The move aligns with broader industry trends, following similar investments announced by Roche, Johnson & Johnson, and Novartis, and comes amid continued calls from policymakers to strengthen domestic pharmaceutical manufacturing.
“Sanofi’s 13,000 U.S.-based employees are pioneering the research and development of first- and best-in-class medicines across numerous therapeutic areas,” said CEO Paul Hudson. “Our expected investments in the U.S. will be substantial and will help ensure the production of key medicines here at home.”
As part of the initiative, Sanofi will significantly increase its U.S. R&D spending to accelerate the development of innovative therapies. The company also plans to expand manufacturing capacity across its existing facilities and through partnerships with American manufacturers, aiming to reinforce the local production of essential medicines.
Sanofi Frankfurt Hq Picture by Sanofi de
